MCID: PRM126
MIFTS: 47

Primary Peritoneal Carcinoma malady

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Primary Peritoneal Carcinoma

About this section
Sources:
51Orphanet, 65UMLS, 28ICD10 via Orphanet
See all MalaCards sources

Aliases & Descriptions for Primary Peritoneal Carcinoma:

Name: Primary Peritoneal Carcinoma 51 65
Serous Surface Papillary Carcinoma 51 65
Extra-Ovarian Primary Peritoneal Carcinoma 51
Primary Peritoneal Serous Adenocarcinoma 65
 
Primary Peritoneal Serous Carcinoma 51
Eoppc 51
Ppc 51

Characteristics:

Orphanet epidemiological data:

51
serous surface papillary carcinoma:
Age of onset: Adult; Age of death: normal life expectancy

Classifications:

Orphanet: 51 
Rare tumors


External Ids:

Orphanet51 168829
ICD10 via Orphanet28 C48.2
UMLS65 C1514428

Summaries for Primary Peritoneal Carcinoma

About this section
Wikipedia:68 Primary peritoneal cancer or carcinoma is also known as serous surface papillary carcinoma, primary... more...

MalaCards based summary: Primary Peritoneal Carcinoma, also known as serous surface papillary carcinoma, is related to papillary serous adenocarcinoma and ovary papillary carcinoma, and has symptoms including weight loss, nausea and vomiting and constipation. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (Breast Cancer 1), and among its related pathways are ATF-2 transcription factor network and Fanconi anemia pathway. Affiliated tissues include breast, ovary and liver, and related mouse phenotypes are respiratory system and limbs/digits/tail.

Related Diseases for Primary Peritoneal Carcinoma

About this section

Diseases in the Peritoneal Benign Neoplasm family:

primary peritoneal carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 253)
idRelated DiseaseScoreTop Affiliating Genes
1papillary serous adenocarcinoma11.9
2ovary papillary carcinoma11.7
3congenital pulmonary veins atresia or stenosis10.6BRCA1, BRCA2
4bronchiolitis obliterans10.5BRCA1, BRCA2
5breast cancer, childhood10.5BRCA1, BRCA2
6brca2 hereditary breast and ovarian cancer syndrome10.5BRCA1, BRCA2
7pancreatic cancer 410.5BRCA1, BRCA2
8glaucoma iridogoniodysgenesia10.4ERBB2, PGR
9cycloplegia10.4IFNG, IL10
10autoimmune disease of urogenital tract10.4BRCA1, BRCA2, PGR
11malignant testicular leydig cell tumor10.4BRCA1, BRCA2, PGR
12thyroid carcinoma with thyrotoxicosis10.4ERBB2, RET
13mastitis10.4BRCA1, BRCA2
14vulvar alveolar soft part sarcoma10.4BRCA1, BRCA2, PGR
15bile duct mucoepidermoid carcinoma10.4ERBB2, PGR
16ganglioglioma10.4
17flat ductal epithelial atypia10.4EGFR, ERBB2
18ureter adenocarcinoma10.4ERBB2, PGR
19cerebellar liponeurocytoma10.4BRCA1, BRCA2, RET
20autoimmune polyendocrine syndrome type 110.3BRCA1, BRCA2, ERBB2
21metachronous kidney wilms' tumor10.3PGR, TP53
22childhood choriocarcinoma of the ovary10.3BRCA1, ERBB2, PGR
23esophageal adenoid cystic carcinoma10.3EGFR, PGR
24dental pulp calcification10.3BRCA1, ERBB2, PGR
25ovarian cancer, somatic10.3BRCA1, BRCA2, ERBB2
26breast benign neoplasm10.3BRCA1, ERBB2, PGR
27graft-versus-host disease, protection against10.3IFNG, IL10
28deep leiomyoma10.3PGR, TP53
29red cell phospholipid defect with hemolysis10.3EGFR, IFNG
30gastric papillary adenocarcinoma10.3ERBB2, PGR, RET
31peripheral retinal degeneration10.3CXCL8, IFNG, IL10
32astrakhan spotted fever10.3CXCL8, IFNG, IL10
33leech infestation10.3CXCL8, IFNG, IL10
34dentin dysplasia10.3CXCL8, IFNG, IL10
35bronchopulmonary dysplasia10.3CXCL8, IFNG, IL10
36ovary neuroendocrine neoplasm10.3PGR, TP53
37eosinophilic gastritis10.3CXCL8, IFNG, IL10
38liver lipoma10.3CXCL8, IFNG, IL10
39glycoproteinosis10.3CXCL8, IFNG, IL10
40multiple symmetric lipomatosis10.3CXCL8, IFNG, IL10
41long bone adamantinoma10.3CXCL8, IFNG, IL10
42diffuse scleroderma10.2CXCL8, IFNG, IL10
43lymphatic system disease10.2EGFR, TP53
44severe acute respiratory syndrome10.2CXCL8, IFNG, IL10
45eyelid degenerative disease10.2CXCL8, IFNG, IL10
46hypogonadotropic hypogonadism-frontoparietal alopecia syndrome10.2EGFR, TP53
47mutiple parosteal osteochondromatous proliferations10.2BRCA1, BRCA2, TP53
48mononeuritis of lower limb10.2CXCL8, IFNG, IL10
49tetrasomy 2110.2BRCA1, BRCA2, TP53
50adenofibroma10.2EGFR, ERBB2, PGR

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to primary peritoneal carcinoma

Symptoms for Primary Peritoneal Carcinoma

About this section

Symptoms:

 51 (show all 9)
  • anomalies of the abdominal wall
  • nausea/vomiting/regurgitation/merycism/hyperemesis
  • acute abdominal pain/colic
  • constipation
  • peritoneal diseases
  • neoplasms/tumors
  • ovary/fallopian tube neoplasm/tumor/carcinoma/cancer (excl. teratoma/germinoma)
  • weight loss/loss of appetite/break in weight curve/general health alteration
  • early death/lethality

HPO human phenotypes related to Primary Peritoneal Carcinoma:

(show all 7)
id Description Frequency HPO Source Accession
1 weight loss hallmark (90%) HP:0001824
2 nausea and vomiting hallmark (90%) HP:0002017
3 constipation hallmark (90%) HP:0002019
4 abdominal pain hallmark (90%) HP:0002027
5 abnormality of the peritoneum hallmark (90%) HP:0002585
6 abnormality of the abdominal wall hallmark (90%) HP:0004298
7 ovarian neoplasm hallmark (90%) HP:0100615

Drugs & Therapeutics for Primary Peritoneal Carcinoma

About this section

Drugs for Primary Peritoneal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 261)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
2
FluorouracilapprovedPhase 3, Phase 2, Phase 1168451-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
3
GemcitabineapprovedPhase 3, Phase 2, Phase 1188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
4
Doxorubicinapproved, investigationalPhase 3, Phase 2, Phase 1158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
5
PaclitaxelapprovedPhase 3, Phase 2, Phase 1262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
6
AlvimopanapprovedPhase 318156053-89-3, 170098-38-15488548
Synonyms:
156053-89-3
170098-38-1 (dihydrate)
2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
AC1NUQN6
ADL 8-2698
Adl 8-2698
Alvimopan
Alvimopan anhydrous
 
CHEMBL270190
CID5488548
DB06274
Entereg
Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl
I06-1921
LY 246736
LY246736
UNII-Q153V49P3Z
trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine
7
CisplatinapprovedPhase 3, Phase 2, Phase 1254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
8
Topotecanapproved, investigationalPhase 3, Phase 2, Phase 1330119413-54-660700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
MLS000759456
 
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
9
TamoxifenapprovedPhase 3, Phase 235010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Soltamox
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
10
Irinotecanapproved, investigationalPhase 3, Phase 2, Phase 1104497682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
11
CarboplatinapprovedPhase 3, Phase 2, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
12
Bevacizumabapproved, investigationalPhase 3, Phase 2, Phase 11875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
13
Oxaliplatinapproved, investigationalPhase 3, Phase 2, Phase 1132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
14
leucovorinapprovedPhase 3, Phase 2, Phase 19521492-18-854575
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid-SF
Fusilev
 
L-Folinic acid
L-leucovorin
Leucal
Leucovorin
Leucovorin Calcium
Leucovorin calcium
Leucovorin folinic acid
Leucovorin sodium
Leukovorin
Levofolene
Levofolinic acid
Levoleucovorin
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
Wellcovorin
15
PancrelipaseapprovedPhase 3, Phase 288053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
Creon
PA
Pancreatic alpha-amylase precursor
Pancreaze
 
Pancrelipase
Pertzye
Polocaine-mpf
Ultresa
Viokace
Zenpep
16
SuccinylcholineapprovedPhase 3, Phase 1, Phase 2141306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
17
MechlorethamineapprovedPhase 2, Phase 330951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
18
TrametinibapprovedPhase 2, Phase 3111871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
19
Letrozoleapproved, investigationalPhase 2, Phase 3358112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
20
IfosfamideapprovedPhase 2, Phase 33713778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
21
OlaparibapprovedPhase 2, Phase 3, Phase 1104763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
22
Pyridoxineapproved, nutraceuticalPhase 316565-23-61054
Synonyms:
(5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate
12001-78-4
2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]
2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine
2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine
2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-methyl-4,5-dimethylol-pyridin-3-ol
2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0
3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride
3-Hydroxy-2-Picoline-4,5-dimethanol
3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride
3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride
3-Hydroxy-4,5-dimethylol-alpha-picoline
3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride
3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol
4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride
4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol
4-Deoxypyridoxine 5'-phosphate
47862_SUPELCO
5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol
5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
58-56-0
58-56-0 (HCL)
58-56-0 (hydrochloride)
65-23-6
65-23-6 (Parent)
8059-24-3
85078-23-5
AC-12024
AC-14512
AC-907/25014218
AC1L1AMH
AC1L1LMI
AC1L2XK2
AC1Q22HP
AC1Q2G66
AC1Q3F63
AI3-19016
AIDS-006784
AIDS006784
AR-1A6363
AR-1J1632
Adermin hydrochloride
Adermine
Adermine hydrochloride
Aderomine hydrochloride
Aderoxin
Aderoxine
Alestrol
BB_NC-0050
BIDD:PXR0180
BPBio1_000646
BSPBio_000586
Becilan
Beesix
Benadon
Bonasanit
C00314
C8H11NO3
CAS-58-56-0
CBDivE_015627
CCRIS 1903
CHEBI:16709
CHEBI:30961
CHEMBL1200756
CHEMBL1364
CID104817
CID1054
CID6019
CPD0-1221
Campoviton 6
Cernevit-12
D02179
D025101
D08454
DB00165
EINECS 200-386-2
EINECS 200-603-0
EINECS 232-503-8
Godabion
Gravidox
HMS1569N08
HMS2093L07
HSDB 1212
Hexa-Betalin
Hexa-Betalin (R)
Hexa-betalin (TN)
Hexabetalin
Hexabione hydrochloride
Hexavibex
 
Hexermin
Hexermine
Hexobion
Hydoxin
I02-1897
I02-2297
KST-1A8556
LS-134393
LS-187072
LS-2332
MLS001074329
MLS002153915
MolPort-002-137-856
MolPort-002-319-991
MolPort-005-933-330
NCGC00016261-01
NCGC00164317-01
NCGC00180946-01
NSC 36225
NSC36225
NSC36225 (HCL)
Nestrex
Oprea1_061614
P0561
P4722_SIAL
P5669_SIGMA
P6280_SIGMA
P8666_SIGMA
P9755_SIAL
PN
PN HCl
PYRIDOXINE HYDROCHLORIDE
PYRIDOXINE HYDROCHLORIDE, U.S.P.
Paxadon
Piridossina
Piridossina [DCIT]
Piridoxina
Piridoxina [INN-Spanish]
Prestwick0_000623
Prestwick1_000623
Prestwick2_000623
Prestwick3_000623
Prestwick_925
Pydox
Pyridipca
Pyridox
Pyridoxin
Pyridoxin hydrochloride
Pyridoxine
Pyridoxine (INN)
Pyridoxine HCl
Pyridoxine Hydrochloride
Pyridoxine Hydrochloride (B6)
Pyridoxine [INN:BAN]
Pyridoxine chloride
Pyridoxine hydrochloride
Pyridoxine hydrochloride (JP15/USP)
Pyridoxine hydrochloride [USAN:JAN]
Pyridoxine hydrogen chloride
Pyridoxine monohydrochloride
Pyridoxine, hydrochloride
Pyridoxine-HCl Microencapsulated
Pyridoxinium chloride
Pyridoxinum
Pyridoxinum [INN-Latin]
Pyridoxinum hydrochloricum
Pyridoxinum hydrochloricum (Hungarian)
Pyridoxol
Pyridoxol hydrochloride
Pyridoxol, hydrochloride
Pyridoxolum
Rodex
Rodex (R)
Rodex TD
SMP2_000230
SMR000674613
SPBio_002805
STK177324
STOCK1N-08684
Spondylonal
Tex Six T.R.
TimTec1_000657
UNII-68Y4CF58BV
UNII-KV2JZ1BI6Z
Vitamin B 6
Vitamin B6
Vitamin B6-hydrochloride
Vitamin V6
Vitamin V6 (TN)
Vitamin-?B6
Vitamin-?B6 hydrochloride
Vitaped
WLN: T6NJ B1 CQ D1Q E1Q &GH
ZINC00049154
ZINC21983293
bmse000288
c1302
component of Alestrol
nchembio.93-comp1
pyridoxine
vitamin B6
23
Pyridoxalapproved, nutraceuticalPhase 316365-22-5, 66-72-81050
Synonyms:
3-HYDROXY-5-(hydroxymethyl)-2-methylisonicotinaldehyde
 
3-Hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
Pyridoxal
Pyridoxaldehyde
24
Folic Acidapproved, nutraceuticalPhase 3, Phase 2, Phase 1292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
25
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 2, Phase 11844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
26
Maleic acidexperimentalPhase 2, Phase 3, Phase 1274110-16-7444972, 444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
27
DoxilApproved June 1999Phase 3, Phase 2, Phase 1158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
28Antiviral AgentsPhase 3, Phase 2, Phase 18071
29VitaminsPhase 3, Phase 2, Phase 13857
30Immunologic FactorsPhase 3, Phase 2, Phase 118483
31Anti-Bacterial AgentsPhase 3, Phase 2, Phase 19140
32Vitamin B 6Phase 3165
33taxanePhase 3, Phase 2, Phase 1324
34MitomycinsPhase 3, Phase 1, Phase 2219
35MicronutrientsPhase 3, Phase 2, Phase 13901
36Trace ElementsPhase 3, Phase 2, Phase 13900
37LevoleucovorinPhase 3, Phase 2, Phase 1676
38Vitamin B ComplexPhase 3, Phase 2, Phase 12847
39Protective AgentsPhase 3, Phase 2, Phase 15651
40AntimetabolitesPhase 3, Phase 2, Phase 19454
41Antineoplastic Agents, AlkylatingPhase 2, Phase 3, Phase 13406
42Angiogenesis Modulating AgentsPhase 3, Phase 2, Phase 13611
43Anti-Infective AgentsPhase 3, Phase 2, Phase 117220
44Antibiotics, AntitubercularPhase 3, Phase 2, Phase 15971
45Pharmaceutical SolutionsPhase 3, Phase 2, Phase 17004
46Alkylating AgentsPhase 2, Phase 3, Phase 13582
47Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 15770
48
CediranibPhase 2, Phase 3, Phase 1879933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
49pancreatic polypeptidePhase 3, Phase 120
50Poly(ADP-ribose) Polymerase InhibitorsPhase 2, Phase 3, Phase 1250

Interventional clinical trials:

(show top 50)    (show all 399)
idNameStatusNCT IDPhase
1Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00011986Phase 3
2A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerCompletedNCT01239732Phase 3
3Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian CancerCompletedNCT00003322Phase 3
4Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00002717Phase 3
5Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00041080Phase 3
6Accelerating Gastrointestinal RecoveryCompletedNCT01704651Phase 3
7A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube CarcinomaCompletedNCT00434642Phase 3
8Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3
9Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00075712Phase 2, Phase 3
10Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerCompletedNCT00483782Phase 3
11An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior ChemotherapyCompletedNCT00191646Phase 3
12Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00003636Phase 3
13S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian CancerCompletedNCT00043082Phase 3
14Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
15Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal AdenocarcinomasCompletedNCT00443196Phase 2, Phase 3
16Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for CancerCompletedNCT00245050Phase 3
17Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA TrialCompletedNCT00941655Phase 3
18Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal CarcinomatosisCompletedNCT01524094Phase 3
19Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT02502266Phase 2, Phase 3
20Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube CancerRecruitingNCT00565851Phase 3
21Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT02446600Phase 3
22Intraperitoneal Therapy For Ovarian Cancer With Carboplatin TrialRecruitingNCT01506856Phase 2, Phase 3
23Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerRecruitingNCT02101788Phase 2, Phase 3
24Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?RecruitingNCT01611766Phase 3
25Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT00719303Phase 3
26ICON8: Weekly Chemotherapy in Ovarian CancerRecruitingNCT01654146Phase 3
27Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerRecruitingNCT00045461Phase 2, Phase 3
28Surgical Complications Related to Primary or Interval Debulking in Ovarian NeoplasmRecruitingNCT01461850Phase 3
29Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal CarcinomatosisRecruitingNCT02179489Phase 3
30D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric CarcinomaRecruitingNCT01882933Phase 3
31Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal PatientsRecruitingNCT01226394Phase 3
32Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric CancerRecruitingNCT01683864Phase 2, Phase 3
33Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal CarcinomaActive, not recruitingNCT02328716Phase 3
34Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerActive, not recruitingNCT00951496Phase 3
35Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerActive, not recruitingNCT00954174Phase 3
36Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerActive, not recruitingNCT01167712Phase 3
37Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube CancerActive, not recruitingNCT00108745Phase 3
38Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian CarcinomaActive, not recruitingNCT00226915Phase 3
39Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and ChemotherapyActive, not recruitingNCT00004115Phase 3
40Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian CancerActive, not recruitingNCT01462890Phase 3
41An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian CancerActive, not recruitingNCT00532194Phase 3
42A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingNCT01849874Phase 3
43Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal CancerTerminatedNCT00047632Phase 3
44Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal CancerTerminatedNCT00003880Phase 2, Phase 3
45Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing ChemotherapyWithdrawnNCT01492920Phase 3
46Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaCompletedNCT01381861Phase 2
47Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal CarcinomaCompletedNCT00868192Phase 2
48Study of Ramucirumab in Ovarian CancerCompletedNCT00721162Phase 2
49A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaCompletedNCT00671788Phase 2
50Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNCT00193297Phase 2

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

About this section

Anatomical Context for Primary Peritoneal Carcinoma

About this section

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

33
Breast, Ovary, Liver, T cells, Lung, Appendix, Lymph node

Animal Models for Primary Peritoneal Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

38 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.7BRCA1, EGFR, ERBB2, IFNG, IL10, RET
2MP:00053718.5BRCA1, BRCA2, EGFR, ERBB2, IL10, PGR
3MP:00053818.5BRCA1, BRCA2, EGFR, ERBB2, IFNG, IL10
4MP:00028738.3BRCA1, BRCA2, EGFR, ERBB2, IFNG, IL10
5MP:00053868.3BRCA1, BRCA2, ERBB2, ERCC1, IFNG, IL10
6MP:00107718.2BRCA1, BRCA2, EGFR, ERBB2, ERCC1, IFNG
7MP:00053698.1BRCA1, EGFR, ERBB2, ERCC1, IFNG, IL10
8MP:00053808.0BRCA1, BRCA2, EGFR, ERBB2, ERCC1, IFNG
9MP:00053798.0BRCA1, BRCA2, EGFR, ERBB2, ERCC1, IFNG
10MP:00020068.0BRCA1, BRCA2, EGFR, ERBB2, ERCC1, IFNG
11MP:00053897.9BRCA1, BRCA2, EGFR, ERBB2, ERCC1, IFNG
12MP:00053907.9BRCA1, BRCA2, EGFR, ERBB2, ERCC1, IFNG
13MP:00053857.9BRCA1, CXCL10, EGFR, ERBB2, IFNG, IL10
14MP:00053877.6BRCA1, BRCA2, CXCL10, EGFR, ERCC1, IFNG
15MP:00053977.6BRCA1, BRCA2, CXCL10, EGFR, ERCC1, IFNG
16MP:00053847.4BRCA1, BRCA2, CXCL10, EGFR, ERBB2, ERCC1
17MP:00053767.4BRCA1, BRCA2, CXCL10, EGFR, ERBB2, ERCC1
18MP:00107687.4BRCA1, BRCA2, CXCL10, EGFR, ERBB2, ERCC1

Publications for Primary Peritoneal Carcinoma

About this section

Articles related to Primary Peritoneal Carcinoma:

(show top 50)    (show all 118)
idTitleAuthorsYear
1
DAP5 associates with eIF2I^ and eIF4AI to promote Internal Ribosome Entry Site driven translation. (25779044)
2015
2
Modular cognitive-behavioral therapy for body dysmorphic disorder: a randomized controlled trial. (24680228)
2014
3
Novel implications of Lingo-1 and its signaling partners in schizophrenia. (24448210)
2014
4
Treatment of recurrent intrahepatic cholangiocarcinoma. (23132419)
2012
5
Reply to commentary on "a case of erdheim-chester disease with asymptomatic renal involvement". (23341795)
2012
6
Biochemical characterization of Warsaw breakage syndrome helicase. (22102414)
2012
7
ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. (22915242)
2012
8
Primary thyroid lymphoma with elevated free thyroxine level. (21947158)
2011
9
Mutations in the TSGA14 gene in families with autism spectrum disorders. (21438139)
2011
10
Irregular heavy drinking occasions and risk of ischemic heart disease: a systematic review and meta-analysis. (20142394)
2010
11
Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma]. (20038314)
2010
12
Invasive cutaneous angiomatosis and thrombocytopenia in a cat. (19210261)
2009
13
Interaction between Poly(ADP-ribose) and NuMA contributes to mitotic spindle pole assembly. (19759176)
2009
14
Regulation of fibroblast mitochondrial 27-hydroxycholesterol production by active plasma membrane cholesterol. (19401598)
2009
15
Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. (17671970)
2008
16
Identification of two de novo mutations in Chinese patients with X-linked adrenoleukodystrophy. (18973459)
2008
17
Peptide YY (3-36) represents a high percentage of total PYY immunoreactivity in preterm and full-term infants and correlates independently with markers of adiposity and serum ghrelin concentrations. (17597642)
2007
18
Neurological disorders in patients with bullous pemphigoid. (17823513)
2007
19
Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility. (17955236)
2007
20
More TORC for the gluconeogenic engine. (16479585)
2006
21
Regulation of the steroidogenic acute regulatory protein expression: functional and physiological consequences. (15777208)
2005
22
Polymorphisms of genes involved in homocysteine metabolism in preeclampsia and in uncomplicated pregnancies. (15866085)
2005
23
Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. (14969398)
2004
24
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL. (15487457)
2004
25
Parietal foramina with cleidocranial dysplasia is caused by mutation in MSX2. (14571277)
2003
26
Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. (12676457)
2003
27
Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. (12194550)
2002
28
Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. (11818317)
2002
29
The Aspergillus cytoplasmic dynein heavy chain and NUDF localize to microtubule ends and affect microtubule dynamics. (11369237)
2001
30
Elevated serum concentrations of beta-tryptase, but not alpha-tryptase, in Sudden Infant Death Syndrome (SIDS). An investigation of anaphylactic mechanisms. (11696045)
2001
31
Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study. (11005786)
2000
32
Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. (10849444)
2000
33
Effects of phorbol esters on excitation-contraction coupling and protein kinase C activity of frog twitch muscle fibers. (10370088)
1999
34
Numerical abnormalities of chromosome 7 in interphase cell nuclei of breast carcinoma have no impact on immunohistochemically determined EGFR status. (10225319)
1999
35
An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. (9597004)
1998
36
Immunocytochemical detection of p53 protein as an adjunct in cytologic diagnosis from pancreatic duct brushings in mucin-producing tumors of the pancreas. (9196015)
1997
37
The syndrome of hypoparathyroidism, severe growth failure, developmental delay and distinctive facies. (9220193)
1997
38
The ubiquitous VA68 isoform of subunit A of the vacuolar H(+)-ATPase is highly expressed in human osteoclasts. (7575517)
1995
39
Lymphocytic choriomeningitis virus induces a chronic wasting disease in mice lacking class I major histocompatibility complex glycoproteins. (8103060)
1993
40
Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. (8475068)
1993
41
Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. (7693093)
1993
42
Serum IgG reactivity with 41-, 31-, and 28-kDa larval proteins of Strongyloides stercoralis in individuals with strongyloidiasis. (8354924)
1993
43
The treatment basis for anticoagulants in horses]. (2264055)
1990
44
Autoimmunity in rapidly progressive glomerulonephritis. (2651770)
1989
45
The role of Chlamydia trachomatis in epididymitis. (3690209)
1987
46
Relationship between sibship size and neurotic symptoms of anxiety, hypochondriasis and depression in Japanese neurotic children and adolescents. (3833626)
1985
47
Case report: ossifying fibroma associated with an endodontically treated tooth. (6954132)
1982
48
Clinical assessment of hetacillin in acute diarrhea of malnourished infants. (4998182)
1967
49
Impairment of muscle stretch reflexes in tick paralysis. (13697384)
1960
50
LAPffler's syndrome; periarteritis nodosa. (18128527)
1949

Variations for Primary Peritoneal Carcinoma

About this section

Cosmic variations for Primary Peritoneal Carcinoma:

7 (show top 50)    (show all 75)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
2COSM44603TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
3COSM44603TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
4COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
5COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
6COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
7COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
8COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
9COSM44603TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
10COSM44338TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
11COSM43989TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
12COSM43989TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
13COSM43989TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
14COSM43989TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
15COSM43989TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
16COSM44338TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
17COSM44338TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
18COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
19COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
20COSM44769TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
21COSM44769TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
22COSM44764TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
23COSM44769TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
24COSM44684TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
25COSM44684TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
26COSM44684TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
27COSM44764TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
28COSM44764TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
29COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
30COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
31COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
32COSM44683TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
33COSM44764TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
34COSM44764TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
35COSM44764TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
36COSM43989TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
37COSM43989TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
38COSM10794TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
39COSM10758TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
40COSM10758TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
41COSM10794TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
42COSM10794TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
43COSM10988TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
44COSM10988TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
45COSM10758TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
46COSM10704TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
47COSM10704TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
48COSM10662TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
49COSM10662TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3
50COSM10704TP53peritoneum,NS,carcinoma,peritoneal serous surface carcinoma3

Expression for genes affiliated with Primary Peritoneal Carcinoma

About this section
Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for genes affiliated with Primary Peritoneal Carcinoma

About this section

Pathways related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
idSuper pathwaysScoreTop Affiliating Genes
19.7BRCA1, CXCL8, IFNG
2
Show member pathways
9.7BRCA1, BRCA2, ERCC1
39.6CXCL8, IFNG, IL10
49.6CXCL8, IFNG, IL10
5
Show member pathways
9.6BRCA1, BRCA2, TP53
69.6BRCA1, BRCA2, TP53
79.5EGFR, IFNG, IL10
89.5CXCL8, IFNG, TP53
99.5CXCL8, IFNG, TP53
109.3EGFR, ERBB2, TP53
119.2BRCA1, BRCA2, EGFR, TP53
12
Show member pathways
9.1BRCA2, EGFR, ERBB2, TP53
139.0EGFR, ERBB2, RET, TP53
149.0CXCL8, EGFR, ERBB2, TP53
158.9BRCA1, BRCA2, EGFR, ERBB2, TP53
16
Show member pathways
8.9BRCA1, BRCA2, EGFR, ERBB2, TP53
17
Show member pathways
8.8CXCL10, CXCL8, IFNG, IL10, TP53
188.7CXCL10, CXCL8, EGFR, IFNG, TP53
198.6MIR195, MIR497, TP53
208.5BRCA2, CXCL8, EGFR, ERBB2, RET, TP53
218.5BRCA1, EGFR, ERBB2, MIR195, TP53

GO Terms for genes affiliated with Primary Peritoneal Carcinoma

About this section

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1defense response to protozoanGO:004283210.5IFNG, IL10
2negative regulation of growth of symbiont in hostGO:004413010.5IFNG, IL10
3chordate embryonic developmentGO:004300910.4BRCA1, BRCA2
4positive regulation of MHC class II biosynthetic processGO:004534810.3IFNG, IL10
5DNA recombinationGO:000631010.1BRCA1, BRCA2, ERCC1
6response to nutrientGO:000758410.1BRCA1, BRCA2, ERCC1
7cell cycle arrestGO:000705010.0CXCL8, IFNG, TP53
8transmembrane receptor protein tyrosine kinase signaling pathwayGO:000716910.0EGFR, ERBB2, RET
9DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.9BRCA1, BRCA2, TP53
10response to gamma radiationGO:00103329.7BRCA2, CXCL10, TP53
11positive regulation of transcription, DNA-templatedGO:00458939.4BRCA2, IFNG, IL10, RET, TP53
12cellular response to DNA damage stimulusGO:00069749.3BRCA1, BRCA2, ERCC1, TP53
13immune responseGO:00069559.1CXCL10, CXCL8, IFNG, IL10
14positive regulation of transcription from RNA polymerase II promoterGO:00459448.4BRCA1, CXCL10, EGFR, IFNG, IL10, TP53

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor signaling protein tyrosine kinase activityGO:00047169.8EGFR, ERBB2

Sources for Primary Peritoneal Carcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet